{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460016695
| IUPAC_name = Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1''H''-pyrimidin-4-yl]carbamate
| image = Capecitabine.svg
| width = 280px
| image2 = Capecitabine-from-xtal-2009-3D-balls.png
| width2 = 250px
<!--Clinical data-->
| pronounce = {{IPAc-en|k|æ|p|ᵻ|ˈ|s|aɪ|t|ə|b|i|n}} 
| tradename = Xeloda, others
| Drugs.com = {{drugs.com|monograph|capecitabine}}
| MedlinePlus = a699003
| pregnancy_AU = D
| pregnancy_US = D
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = by mouth
<!--Pharmacokinetic data-->
| bioavailability = Extensive
| protein_bound = < 60%
| metabolism = liver, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active [[fluorouracil]]
| elimination_half-life = 38–45 minutes
| excretion = kidney (95.5%), faecal (2.6%)
<!--Identifiers-->
| class         = chemotherapy agent
| IUPHAR_ligand = 6799
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 154361-50-9
| ATC_prefix = L01
| ATC_suffix = BC06
| PubChem = 60953
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01101
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54916
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6804DJ8Z9U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01223
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31348
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1773
<!--Chemical data-->
| C=15 | H=22 | F=1 | N=3 | O=6
| molecular_weight = 359.35 g/mol
| smiles = FC=1\C(=N/C(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)C)\NC(=O)OCCCCC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GAGWJHPBXLXJQN-UORFTKCHSA-N
}}

<!-- Definition and medical uses -->
'''Capecitabine''', sold under the brand name '''Xeloda''' among others, is a [[chemotherapy medication]] used to treat [[breast cancer]], [[gastric cancer]] and [[colorectal cancer]].<ref name=BNF69>{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|pages=585, 588|edition=69}}</ref> For breast cancer it is often used together with [[docetaxel]].<ref name=AHFS2016/> It is taken by mouth.<ref name=AHFS2016>{{cite web|title=Capecitabine|url=https://www.drugs.com/monograph/capecitabine.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160415200439/http://www.drugs.com/monograph/capecitabine.html|archivedate=15 April 2016|df=}}</ref>

<!-- Side effects and mechanism -->
Common side effects include abdominal pain, vomiting, [[diarrhea]], weakness, and rashes.<ref name=AHFS2016/> Other severe side effects include blood clotting problems, [[allergic reactions]], heart problems, and [[cytopenia|low blood cell counts]].<ref name=AHFS2016/> It is not recommended in people with [[kidney problems]].<ref name=AHFS2016/> Use during [[pregnancy]] may result in harm to the baby.<ref name=AHFS2016/> Capecitabine, inside the body, is converted to [[5-fluorouracil]] (5-FU) through which it acts.<ref name=AHFS2016/> It belongs to the class of medications known as [[fluoropyrimidine]]s, which also includes [[5-fluorouracil]] and [[tegafur]].<ref name="pmid23988873">{{cite journal|last1=Caudle|first1=KE|last2=Thorn|first2=CF|last3=Klein|first3=TE|last4=Swen|first4=JJ|last5=McLeod|first5=HL|last6=Diasio|first6=RB|last7=Schwab|first7=M|title=Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.|journal=Clinical pharmacology and therapeutics|date=December 2013|volume=94|issue=6|pages=640–5|doi=10.1038/clpt.2013.172|pmid=23988873|pmc=3831181}}</ref>

<!-- History and culture -->
Capecitabine was patented in 1992 and approved for medical use in 1998.<ref name=Fis2006>{{cite book|last1=Fischer|first1=Janos|last2=Ganellin|first2=C. Robin|title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=511|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA511|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170911002644/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA511|archivedate=2017-09-11|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost in the [[developing world]] is about 122.64 to 195.66 USD per cycle of medication.<ref name=ERC2014>{{cite web|title=Capecitabine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=CAPE500T&s_year=2014&year=2014&str=500%20mg&desc=Capecitabine&pack=new&frm=TAB-CAP&rte=PO&class_code2=08%2E2%2E&supplement=&class_name=%2808%2E2%2E%29Cytotoxic%20and%20adjuvant%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United Kingdom it costs the [[National Health Service|NHS]] about £210.67 per cycle.<ref name=BNF69/> In the United States it costs about 1,892.00 USD as of 2016.<ref>{{cite web|title=NADAC as of 2016-12-07 {{!}} Data.Medicaid.gov|url=https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78|website=Centers for Medicare and Medicaid Services|accessdate=19 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78|archivedate=21 December 2016|df=}}</ref>

==Medical uses==
It is used in the treatment of the following cancers:<ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref><ref name=MSR>{{cite web|title=Xeloda (capecitabine) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|date=25 January 2014|url=http://reference.medscape.com/drug/xeloda-capecitabine-342211#showall|deadurl=no|archiveurl=https://web.archive.org/web/20140202175324/http://reference.medscape.com/drug/xeloda-capecitabine-342211#showall|archivedate=2 February 2014|df=}}</ref><ref name="BNF">{{cite book | isbn = 978-0-85711-084-8 | title = British National Formulary (BNF) | last1 = Joint Formulary Committee | year = 2013 | publisher = Pharmaceutical Press | location = London, UK | edition = 65  | pages =  }}</ref>
* [[Colorectal cancer]] (either as neoadjuvant therapy with radiation, adjuvant therapy or for metastatic cases)
* [[Breast cancer]] (metastatic or as monotherapy/combotherapy; this is licensed as a second-line treatment in the UK)
* [[Gastric cancer]] (off-label in the US; this is a licensed indication in the UK)
* [[Oesophageal cancer]] (off-label in the US)

==Adverse effects==
Adverse effects by frequency:<ref name=DM>{{cite web|title=XELODA (capecitabine) tablet, film coated [Genentech, Inc.]|work=DailyMed|publisher=Genentech, Inc.|date=December 2013|accessdate=25 January 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8|deadurl=no|archiveurl=https://web.archive.org/web/20140201232002/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8|archivedate=1 February 2014|df=}}</ref><ref name=EMA>{{cite web|title=Capecitabine Teva : EPAR – Product Information|work=European Medicines Agency|publisher=Teva Pharma B.V.|date=10 January 2014|accessdate=25 January 2014|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002362/WC500127288.pdf|format=PDF|deadurl=no|archiveurl=https://web.archive.org/web/20140204011552/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002362/WC500127288.pdf|archivedate=4 February 2014|df=}}</ref><ref name=EMC>{{cite web|title=Capecitabine 150mg – Summary of Product Characteristics (SPC)|work=electronic Medicines Compendium|publisher=Zentiva|date=23 December 2013|accessdate=25 January 2014|url=http://www.medicines.org.uk/emc/medicine/28462/SPC/Capecitabine+150mg/|deadurl=no|archiveurl=https://web.archive.org/web/20140201205125/http://www.medicines.org.uk/emc/medicine/28462/SPC/Capecitabine+150mg/|archivedate=1 February 2014|df=}}</ref><ref name=TGA>{{cite web|title=NAME OF THE MEDICINE XELODA® Capecitabine|work=TGA eBusiness Services|publisher=Roche Products Pty Limited|date=5 December 2013|accessdate=25 January 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03462-3|format=PDF|deadurl=no|archiveurl=https://web.archive.org/web/20170911002644/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03462-3|archivedate=11 September 2017|df=}}</ref>

;Very common (>10% frequency):
{{colbegin|4}}
* Appetite loss
* Diarrhea
* Vomiting
* Nausea
* [[Stomatitis]]
* Abdominal pain
* Fatigue
* [[Asthenia|Weakness]]
* [[Hand-foot syndrome]]<ref name = "Notes">Reddening, swelling, numbness and [[desquamation]] on palms and soles</ref>
* [[Oedema]]
* Fever
* Pain
* Headache
* [[Alopecia|Hair loss]]
* [[Dermatitis]]
* [[Dyspepsia|Indigestion]]
* [[Dyspnoea|Shortness of breath]]
* Eye irritation
* Myelosuppression<ref group = "Note">Includes: [[anaemia]], [[lymphopenia]], [[neutropenia]] and [[thrombocytopenia]]</ref>
{{colend}}

Notes on adverse effects:
{{reflist|group = "Note"}}

===Contraindications===
Contraindications include:<ref name = EMC/>
* History of hypersensitivity to fluorouracil, capecitabine or any of its excipients
* [[Dihydropyrimidine dehydrogenase deficiency|DPD deficiency]] (see [[#Pharmacogenetics|Pharmacogenetics]])
* Pregnancy and lactation
* Severe [[leucopenia]], [[neutropenia]], or [[thrombocytopenia]]
* Severe hepatic impairment or severe renal impairment
* Treatment with [[sorivudine]] or its chemically related analogues, such as [[brivudine]]

===Drug interactions===
Drugs it is known to interact with include:<ref name = EMC/>
* [[Sorivudine]] or its analogues, such as, [[brivudine]].
* [[CYP2C9]] substrates, including, [[warfarin]] and other coumarin-derivatives anticoagulants
* [[Phenytoin]], as it increases the plasma concentrations of phenytoin.
* [[Calcium folinate]] may enhance the therapeutic effects of capecitabine by means of synergising with its metabolite, 5-FU. It may also induce more severe diarrhoea by means of this synergy.<ref name = AMH/>

===Pharmacogenetics===
The [[dihydropyrimidine dehydrogenase]] (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes capecitabine, [[5-fluorouracil]] and [[tegafur]].<ref name="pmid23988873">{{cite journal|last1=Caudle|first1=KE|last2=Thorn|first2=CF|last3=Klein|first3=TE|last4=Swen|first4=JJ|last5=McLeod|first5=HL|last6=Diasio|first6=RB|last7=Schwab|first7=M|title=Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.|journal=Clinical pharmacology and therapeutics|date=December 2013|volume=94|issue=6|pages=640–5|doi=10.1038/clpt.2013.172|pmid=23988873|pmc=3831181}}</ref> [[Genetic variation]]s within the DPD gene (''DPYD'') can lead to reduced or absent DPD activity, and individuals who are [[heterozygous]] or [[homozygous]] for these variations may have partial or complete [[DPD deficiency]]; an estimated 0.2% of individuals have complete [[DPD deficiency]].<ref name="pmid23988873"/><ref name="pmid21919607">{{cite journal|last1=Amstutz|first1=U|last2=Froehlich|first2=TK|last3=Largiadèr|first3=CR|title=Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.|journal=Pharmacogenomics|date=September 2011|volume=12|issue=9|pages=1321–36|pmid=21919607|doi=10.2217/pgs.11.72}}</ref> Those with partial or complete DPD deficiency have a significantly increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; examples of toxicities include [[myelosuppression]], [[neurotoxicity]] and [[hand-foot syndrome]].<ref name="pmid23988873"/><ref name="pmid21919607"/>

==Mechanism of action==
{{FluoropyrimidineActivity WP1601|highlight=Capecitabine}}

Capecitabine is metabolised to 5-FU which in turn is a [[thymidylate synthase]] inhibitor, hence inhibiting the synthesis of [[thymidine monophosphate]] (ThMP), the active form of thymidine which is required for the ''de novo'' synthesis of DNA.<ref name = MSR/>

==Society and culture==
One of the brandnames is Xeloda, marketed by [[Genentech]].

==References==
{{reflist|32em}}

==External links==
* [http://www.xeloda.com/ Xeloda.com] (patient information, tools, and resources)

{{Chemotherapeutic agents}}

[[Category:Prodrugs]]
[[Category:Pyrimidones]]
[[Category:Carbamates]]
[[Category:Pyrimidine antagonists]]
[[Category:Organofluorides]]
[[Category:Specialty drugs]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]